Bioinformatics analysis of potential therapeutic targets among genes in breast cancer.

GTPase activating proteins (RhoGAPs) serve significant roles in multiple aspects of tumor biology. Genes encoding RhoGAPs (), which switch off Rho-like GTPases, are responsible for breast cancer biogenesis. However, the identification of suitable and novel biomarkers for precision treatment and prognosis remains challenging. The present study aimed to evaluate the expression of ARHGAP family genes in breast cancer and investigate the survival data using the Oncomine, Kaplan-Meier Plotter, bcGenExMiner and cBioPortal online databases. The results demonstrated low expression of and and high expression of and in patients with breast cancer compared with that in healthy individuals. The survival analysis revealed that low expression levels of and were associated with poor relapse-free survival (RFS) and overall survival (OS), whereas high expression levels of and were associated with preferable RFS and OS. Metastatic relapse data demonstrated that higher expression of and were associated with better prognosis and increased expression of and exerted negative effects on patient prognosis. The overlapping genes and obtained from these bioinformatics analysis tools exhibited significant association with clinical parameters including age, the presence of estrogen receptor, progesterone receptor and epidermal growth factor receptor-2, Scarff-Bloom-Richardson grade and Nottingham prognostic index. In conclusion, bioinformatics analysis revealed that and , but not other ARHGAP family genes may be promising targets with prognostic value and biological function for precision treatment of breast cancer.